Related Experiment Video
Updated: Jul 29, 2026
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
Peritoneal nebulizer: a novel technique for delivering intraperitoneal therapeutics in laparoscopic surgery to
N A Alkhamesi1, P F Ridgway, A Ramwell
1Department of Surgical Oncology and Technology, St. Mary's Hospital, London W2 1NY, United Kingdom. n.alkhamesi@imperial.ac.uk
Background:
Peritoneal involvement is a significant issue in the treatment of gastrointestinal malignancies. Current statistics indicate that after surgical intervention, up to 20% of patients will present with locoregional metastasis. The ability to inhibit initial tumor adhesion to the mesothelial lining of the peritoneum may be considered critical in the inhibition of tumor development. This article describes, the use of a novel nebulizer system capable of delivering high-concentration, low-dose therapeutics to the peritoneal cavity.
Methods:
For this study, 30 male WAG rats were inoculated with CC531 colorectal tumor cells. The rats were randomized into three groups: control group (n = 10), heparin-treated group (n = 10), and high-molecular-weight hyaluronan-treated group (n = 10). A peritoneal cancer index was used to determine tumor burden at 15 days. Analysis of variance (ANOVA) was used to compare multiple group means.
Results:
Nebulization therapy was performed without any complication in the cohort. Heparin inhibited macroscopic intraperitoneal tumor growth completely (p = 0.0001) without affecting tumor cell viability. The introduction of hyaluronan attenuated both tumor size and distribution, was compared with the control group (p = 0.002).
Conclusion:
Nebulized heparin and hyaluronic acid using a novel nebulization technique attenuates peritoneal tumor growth after laparoscopic surgery. The technique itself is easy to use and safe.
Insights
Nebulized heparin and hyaluronic acid significantly reduced peritoneal tumor growth in rats after surgery. This novel nebulization technique offers a safe and effective method for treating gastrointestinal malignancies.
Area of Science:
- Oncology
- Surgical Oncology
- Drug Delivery Systems
Background:
- Peritoneal involvement is a major challenge in gastrointestinal cancer treatment, with up to 20% of patients developing locoregional metastasis post-surgery.
- Inhibiting initial tumor cell adhesion to the peritoneum is crucial for preventing tumor development.
- A novel nebulizer system for delivering high-concentration, low-dose therapeutics to the peritoneal cavity is described.
Purpose of the Study:
- To evaluate the efficacy of nebulized heparin and hyaluronic acid in attenuating peritoneal tumor growth.
- To assess the safety and feasibility of a novel nebulization technique for peritoneal drug delivery.
Main Methods:
- Thirty male WAG rats were inoculated with CC531 colorectal tumor cells and randomized into control, heparin-treated, and high-molecular-weight hyaluronan-treated groups (n=10 each).
- Tumor burden was assessed using a peritoneal cancer index at 15 days post-inoculation.
- Statistical analysis was performed using Analysis of Variance (ANOVA).
Main Results:
- Nebulization therapy was safely administered without complications.
- Heparin completely inhibited macroscopic intraperitoneal tumor growth (p = 0.0001) without impacting tumor cell viability.
- Hyaluronan significantly attenuated tumor size and distribution compared to the control group (p = 0.002).
Conclusions:
- Nebulized heparin and hyaluronic acid, delivered via a novel technique, effectively reduce peritoneal tumor growth following laparoscopic surgery.
- The described nebulization method is safe and easy to implement for therapeutic delivery to the peritoneal cavity.
